Moreover, we found that knockdown of LDB1 significantly enhanced the anti-tumor activity of oxaliplatin in CRC cells, and LDB1 knockdown also partly restored the antitumor effect of oxaliplatin in an oxaliplatin-resistant CRC cell line. The gene discussed is LDB1; the disease is neoplasm.